Biomarkers of Recent Cannabis Use in Blood, Oral Fluid and Breath.


Journal

Journal of analytical toxicology
ISSN: 1945-2403
Titre abrégé: J Anal Toxicol
Pays: England
ID NLM: 7705085

Informations de publication

Date de publication:
17 Sep 2021
Historique:
received: 19 03 2021
revised: 15 06 2021
accepted: 07 07 2021
pubmed: 30 6 2021
medline: 21 9 2021
entrez: 29 6 2021
Statut: ppublish

Résumé

Proving driving under the influence of cannabis (DUIC) is difficult. Establishing a biomarker of recent use to supplement behavioral observations may be a useful alternative strategy. We determined whether cannabinoid concentrations in blood, oral fluid (OF) or breath could identify use within the past 3 h-likely the period of the greatest impairment. In a randomized trial, 191 frequent (≥4/week) and occasional (<4/week) cannabis users smoked one cannabis (placebo [0.02%], or 5.9% or 13.4% Δ9-tetrahydrocannabinol [THC]) cigarette ad libitum. Blood, OF and breath samples were collected prior to and up to 6 h after smoking. Samples were analyzed for 10 cannabinoids in OF, 8 in blood and THC in breath. Frequent users had more residual THC in blood and were more likely to be categorized as 'recently used' prior to smoking; this did not occur in OF. Per se limits ranging from undetectable to 5 ng/mL THC in blood offered limited usefulness as biomarkers of recent use. Cannabinol (CBN, cutoff = 1 ng/mL) in blood offered 100% specificity but only 31.4% sensitivity, resulting in 100% positive predictive value (PPV) and 94.0% negative predictive value (NPV) at 4.3% prevalence; however, CBN may vary by cannabis chemovar. A 10 ng/mL THC cutoff in OF exhibited the overall highest performance to detect its use within 3 h (99.7% specificity, 82.4% sensitivity, 92.5% PPV and 99.2% NPV) but was still detectable in 23.2% of participants ∼4.4 h post-smoking, limiting specificity at later time points. OF THC may be a helpful indicator of recent cannabis intake, but this does not equate to impairment. Behavioral assessment of impairment is still required to determine DUIC. This study only involved cannabis inhalation, and additional research evaluating alternative routes of ingestion (i.e., oral) is needed.

Identifiants

pubmed: 34185831
pii: 6311388
doi: 10.1093/jat/bkab080
doi:

Substances chimiques

Biomarkers 0
Cannabinoids 0
Dronabinol 7J8897W37S

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

820-828

Subventions

Organisme : State of California via Assembly Bill 266

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

J A Hubbard (JA)

Department of Pathology, University of California, 10300 Campus Point Drive, Suite 150, San Diego, CA 92121, USA.

M A Hoffman (MA)

Department of Pathology, University of California, 10300 Campus Point Drive, Suite 150, San Diego, CA 92121, USA.

S E Ellis (SE)

Department of Cognitive Science, University of California, 9500 Gilman Drive, San Diego, CA 92092, USA.
Halıcıoğlu Data Science Institute, University of California, 9500 Gilman Drive, San Diego, CA 92092, USA.

P M Sobolesky (PM)

Department of Pathology, University of California, 10300 Campus Point Drive, Suite 150, San Diego, CA 92121, USA.

B E Smith (BE)

Department of Pathology, University of California, 10300 Campus Point Drive, Suite 150, San Diego, CA 92121, USA.

R T Suhandynata (RT)

Department of Pathology, University of California, 10300 Campus Point Drive, Suite 150, San Diego, CA 92121, USA.

E G Sones (EG)

Department of Psychiatry, University of California, 220 Dickinson, Suite B, San Diego, CA 92103, USA.

S K Sanford (SK)

Department of Psychiatry, University of California, 220 Dickinson, Suite B, San Diego, CA 92103, USA.

A Umlauf (A)

Department of Psychiatry, University of California, 220 Dickinson, Suite B, San Diego, CA 92103, USA.

M A Huestis (MA)

Institute for Emerging Health Professions, Thomas Jefferson University, 901 Walnut Street, Philadelphia, PA 19107, USA.

D J Grelotti (DJ)

Department of Psychiatry, University of California, 220 Dickinson, Suite B, San Diego, CA 92103, USA.

I Grant (I)

Department of Psychiatry, University of California, 220 Dickinson, Suite B, San Diego, CA 92103, USA.

T D Marcotte (TD)

Department of Psychiatry, University of California, 220 Dickinson, Suite B, San Diego, CA 92103, USA.

R L Fitzgerald (RL)

Department of Pathology, University of California, 10300 Campus Point Drive, Suite 150, San Diego, CA 92121, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH